Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy: a Pilot Randomized Controlled Trial

NCT07021430 EARLY_PHASE1 NOT_YET_RECRUITING

The purpose of this study is to demonstrate the feasibility, acceptability, and preliminary effectiveness of a focal mass drug administration program for household members of pregnant women to protect against malaria in pregnancy.

Details

Lead sponsor	University of North Carolina, Chapel Hill
Phase	EARLY_PHASE1
Status	NOT_YET_RECRUITING
Enrolment	300
Start date	2026-04
Completion	2028-04

Conditions

• Malaria Prevention

Interventions

• Dihydroartemisinin Piperaquine

Primary outcomes

• Percent of eligible household members receiving fMDA — Day 1 to study completion, generally 5 months
  Proportion of eligible household members that receive fMDA intervention according to dosing schedule (i.e., one time or monthly)

Countries

Uganda